Berliner Tageblatt - HPV Vaccine Uptake Drops in Ireland as Cervical Cancer Rates Continue to Fall

NYSE - LSE
RELX -0.75% 38.54 $
GSK -0.13% 47.76 $
BTI -1.11% 56.84 $
RBGPF -0.4% 75 $
NGG 0.13% 79.82 $
RYCEF -7.13% 16.4 $
BCE 2.42% 21.86 $
RIO -2.71% 72.73 $
CMSD -0.54% 18.65 $
CMSC -1.35% 18.9 $
VOD -1.15% 14.02 $
BP -1.08% 42.75 $
AZN -0.61% 174.35 $
BCC -2.17% 63.01 $
JRI -1.71% 10.53 $
HPV Vaccine Uptake Drops in Ireland as Cervical Cancer Rates Continue to Fall
HPV Vaccine Uptake Drops in Ireland as Cervical Cancer Rates Continue to Fall

HPV Vaccine Uptake Drops in Ireland as Cervical Cancer Rates Continue to Fall

Ireland’s progress toward eliminating cervical cancer faces a significant hurdle as new data shows a decline in HPV vaccination uptake among young girls. While cancer incidence rates continue to drop, health officials warn that current immunization levels are insufficient to meet the World Health Organization’s targets for disease eradication by 2040.

Text size:

Ireland’s efforts to eliminate cervical cancer by 2040 are being challenged by a recent decline in HPV vaccination rates among young girls, even as the incidence of the disease continues to fall. A new progress report on the national action plan reveals that while public health indicators remain positive, immunization coverage has dropped below the critical threshold required for long-term eradication.

The report, published to coincide with World Cervical Cancer Elimination Day on November 17, shows that 81.2 per cent of girls aged 14 received the HPV vaccine in 2024. This figure represents a decrease of 2.8 percentage points from 2022 levels. The uptake rate remains below the 90 per cent coverage target established by the World Health Organization (WHO), which is considered necessary to make cervical cancer a rare disease.

Despite the drop in vaccination numbers, the report highlights continued progress in reducing cancer rates. Based on European standards, the average annual incidence of cervical cancer fell from 11 cases per 100,000 women in the 2021-2023 period to 10.2 per 100,000 in 2022-2024. When assessed against the WHO’s standard World Female Population 2015 baseline, the rate dropped from 9.0 to 8.1 over the same periods, reaching 7.5 in 2024.

The WHO defines cervical cancer elimination as achieving incidence rates below four new cases per 100,000 women per year. Report authors state that Ireland is on track to reach this threshold by 2040, provided specific conditions are met. These include raising HPV vaccination rates among girls to 90 per cent, ensuring cervical screening levels among women aged 35-45 reach at least 70 per cent, and treating 90 per cent of women identified with cervical disease.

The report notes that current screening coverage and the timely treatment of cervical cancer are already above the WHO’s 90-70-90 targets. However, officials emphasize that increasing vaccination uptake remains a priority to sustain this momentum.

Dr. Colm Henry, the Health Service Executive’s chief clinical officer, wrote in the report’s foreword that while progress highlights the benefits of coordinated action, significant challenges remain. He pointed out that HPV vaccination rates among girls have fallen since 2022, with notably lower uptake in DEIS (Delivering Equality of Opportunity in Schools) schools compared to non-DEIS institutions.

"We must address this decline and rebuild momentum towards the 90 per cent HPV vaccination target by 2030," Dr. Henry said. He added that strong oversight and local ownership will be essential as the country moves into the next phase of the Action Plan.

To strengthen accountability, the Cervical Cancer Elimination Oversight Committee will continue to monitor progress and ensure that plan actions translate into meaningful improvements. The inclusion of a Regional Executive Officer representative on the committee aims to further connect national oversight with delivery at the regional level. Dr. Henry noted that Health Regions have a critical role in implementation, identifying local priorities, and addressing inequalities in access to vaccination, screening, and treatment.

The report also includes reflections from Dr. Caroline Mason Mohan, who recently retired as director of public health with the National Screening Service and cervical cancer elimination lead. In her foreword, she praised the commitment of colleagues working to improve prevention and care across Ireland over the past two years.

Dr. Mason Mohan expressed pride in the progress made in expanding access to HPV vaccination and cervical screening through work with Community Champions. She emphasized that listening to communities is vital for improving access in ways that meet their needs and enhance the experiences of women and their families.

The publication of this second progress report underscores the dual reality of Ireland’s public health landscape: while medical interventions are successfully reducing cancer rates, maintaining high levels of preventive vaccination among younger generations remains a complex logistical and social challenge. Health officials continue to urge communities to support immunization efforts to ensure the 2040 elimination goal is met.

F.Pavlenko--BTB